Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743494 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 794
- Enrollment target
NCT02743494: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02743494 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 794 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02743494, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 794 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
Primary Outcome
Disease-free survival is defined as the time between randomization date and first date of recurrence or death, whichever occurs first. Recurrence is defined as the appearance of one or more new lesions, which can be local, regional, or distant in location from the primary resected site ( assessed by imaging or pathology). All deaths without prior recurrence are considered as DFS events. For participants who remained alive and without recurrence, DFS was censured on the date of last evaluable di
Interventions
- OTHER Placebo
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2016-07-14 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 3 |
What the finished NCT02743494 record still lists
NCT02743494 is an interventional study that assigns participants to a tested intervention. The registered 794 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02743494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02743494 about?
NCT02743494 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer". The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
What is the current status of trial NCT02743494?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 794 participants. The study started on 2016-07-14. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT02743494?
The interventions under investigation include: Placebo (OTHER), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02743494?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02743494's enrollment target sits among peer trials
794 429th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI